1. Home
  2. ACIU vs LPAA Comparison

ACIU vs LPAA Comparison

Compare ACIU & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • LPAA
  • Stock Information
  • Founded
  • ACIU 2003
  • LPAA 2024
  • Country
  • ACIU Switzerland
  • LPAA United States
  • Employees
  • ACIU N/A
  • LPAA N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • LPAA
  • Sector
  • ACIU Health Care
  • LPAA
  • Exchange
  • ACIU Nasdaq
  • LPAA Nasdaq
  • Market Cap
  • ACIU 332.4M
  • LPAA 286.9M
  • IPO Year
  • ACIU 2016
  • LPAA 2024
  • Fundamental
  • Price
  • ACIU $3.15
  • LPAA $10.03
  • Analyst Decision
  • ACIU Strong Buy
  • LPAA
  • Analyst Count
  • ACIU 2
  • LPAA 0
  • Target Price
  • ACIU $12.00
  • LPAA N/A
  • AVG Volume (30 Days)
  • ACIU 151.5K
  • LPAA 85.0K
  • Earning Date
  • ACIU 11-05-2024
  • LPAA 01-01-0001
  • Dividend Yield
  • ACIU N/A
  • LPAA N/A
  • EPS Growth
  • ACIU N/A
  • LPAA N/A
  • EPS
  • ACIU N/A
  • LPAA N/A
  • Revenue
  • ACIU $48,505,404.00
  • LPAA N/A
  • Revenue This Year
  • ACIU $85.33
  • LPAA N/A
  • Revenue Next Year
  • ACIU $80.69
  • LPAA N/A
  • P/E Ratio
  • ACIU N/A
  • LPAA N/A
  • Revenue Growth
  • ACIU 4097200.00
  • LPAA N/A
  • 52 Week Low
  • ACIU $2.25
  • LPAA $9.66
  • 52 Week High
  • ACIU $5.14
  • LPAA $10.03
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 45.68
  • LPAA N/A
  • Support Level
  • ACIU $3.10
  • LPAA N/A
  • Resistance Level
  • ACIU $3.25
  • LPAA N/A
  • Average True Range (ATR)
  • ACIU 0.14
  • LPAA 0.00
  • MACD
  • ACIU -0.02
  • LPAA 0.00
  • Stochastic Oscillator
  • ACIU 13.16
  • LPAA 0.00

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About LPAA Launch One Acquisition Corp. Class A Ordinary shares

Launch One Acquisition Corp is a blank check company.

Share on Social Networks: